BEARINGPOINT
7.3.2023 08:46:35 CET | Business Wire | Press release
Management and technology consultancy BearingPoint closed the year 2022 with record high growth: full-year 2022 adjusted revenues grew 24 percent to €862 million compared to the previous year, mainly driven by new revenue streams and innovative business services. BearingPoint delivered over 1,400 projects for clients in more than 40 countries around the globe. To support its strong development, BearingPoint increased the number of its people by 23 percent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230306005707/en/
Kiumars Hamidian, Managing Partner of BearingPoint. (Photo: Business Wire)
“2022 was an outstanding year for BearingPoint,” said Kiumars Hamidian, Managing Partner of BearingPoint. “Throughout the year, we observed increasing demand for our business services, particularly digital transformation programs. We won significant projects across all market segments, further strengthening our trustful collaboration with clients. In 2023 we want to build on the achievements of 2022, continue to accelerate our strategic ambitions, and target €1 billion in revenue.”
Strategic acquisitions and one joint venture strengthen the BearingPoint portfolio
In 2022 BearingPoint completed four strategic acquisitions that enhanced and strengthened the BearingPoint portfolio, particularly in the areas of sustainability (I Care), financial services (Levo Consultants), digital business transformation (Fekra), as well as the products portfolio (disphere tech). “Our acquisitions are an important component of our strategy execution. Besides organic growth, our strategic M&A activities support our ambitions for the coming years,” said Kiumars Hamidian.
Furthermore, BearingPoint established its first joint venture, Arcwide. The joint venture with IFS brings together professional business services, IFS cloud technology and innovation into a unique business transformation proposition to help companies significantly increase value creation.
With more than 300 people, the Products business unit was another highlight for BearingPoint, recording strong revenue growth of 25 percent. The BearingPoint Store expanded its portfolio of services and solutions to over 20 products. BearingPoint’s products have received both national and international recognition. One of its many awards was the 2022 SAP® Pinnacle Award in the Sustainability category.
A purpose-driven firm
BearingPoint heads into the future as a strong purpose-driven firm, focusing on people, innovation, and sustainability. “In 2022, we jointly refined and clarified our purpose as a team. ‘Together, we are more than business’ is the ideal we put into practice. Personally, I am very proud to see how our people live our purpose. As our people are at the core of our success, we continue to invest in talent development. With more than 2,000 participants in programs like Be.School, Yale, and the Oxford Said Business School, we have created a high-quality training curriculum for our people,” stated Kiumars Hamidian.
2023 – Strategy acceleration
In 2023 BearingPoint will focus on the acceleration of its strategy. The consultancy plans to invest approximately €300 million by 2026, primarily on strategic M&A activities and investments in developing its consulting and products portfolio.
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 13,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005707/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom